In a new study, researchers found that an innovative\nnanoparticle vaccine candidate against SARS-CoV-2 produces levels of\nvirus-neutralizing antibodies in mice that were 10 times higher than those\nrecovered from COVID-19 infection. This candidate vaccine was designed by\nscientists from the University of Washington School of Medicine in Seattle and\nhas been transferred to two companies for clinical development. The relevant\nresearch results were published in Cell<\/em>, and the title of the paper is Elicitation\nof potent neutralizing antibody responses by designed protein nanoparticle\nvaccines for SARS-CoV-2<\/em>.<\/p>\n\n\n\n

Compared with the soluble SARS-CoV-2 spike protein (S\nprotein) on which many leading COVID-19 vaccine candidates are based, this new\nnanoparticle vaccine candidate produces 10 times higher neutralizing antibodies\nin mice, even if the vaccine dose is reduced by 6 times. These data also show\nthat the B cell response after vaccination is strong, which is essential for\nimmune memory and lasting vaccine effect. When injected into a non-human\nprimate, the nanoparticle vaccine produced neutralizing antibodies against many\ndifferent parts of the spike protein. These researchers said that this may\nensure that when variants of the virus appear, these animals can be protected\nfrom the mutant strains of the virus. The spike protein is part of the\nSARS-CoV-2 infection complex.<\/p>\n\n\n\n

\"\" — (UW School of Medicine)<\/figcaption><\/figure><\/div>\n\n\n\n
This candidate vaccine was developed by the structure-based\nvaccine design technology invented by Washington University School of Medicine.\nIt is a self-assembled protein nanoparticle that displays 60 receptor binding\ndomains of the SARS-CoV-2 spike protein in a highly immunogenic array. The\nmolecular structure of this vaccine roughly mimics the molecular structure of\nthis coronavirus, which may be the reason for its ability to trigger an\nenhanced immune response.<\/p>\n\n\n\n
To combat the COVID-19 pandemic, a safe, effective, and scalable vaccine is needed. There are hundreds of COVID-19 vaccine candidates under development globally. And these research results highlight the utility of robust antigen display platforms and have launched cGMP manufacturing efforts to advance the SARS-CoV-2-RBD nanoparticle vaccine into the clinic. The researchers also hope that their nanoparticle platform may help fight this pandemic, and they believe the potency, stability, and manufacturability of this vaccine candidate differentiate it from many others under investigation. <\/p>\n\n\n\n
Reference\uff1a
Walls, A. C., Fiala, B., Sch\u00e4fer, A., Wrenn, S., Pham, M. N., Murphy, M., … & Navarro, M. J. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. *Cell<\/em>, 183(5), 1367-1382. <\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"*
In a new study, researchers found that an innovative nanoparticle vaccine candidate against SARS-CoV-2 produces levels of virus-neutralizing antibodies in<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[59,38],"class_list":["post-237","post","type-post","status-publish","format-standard","hentry","category-applications","tag-sars-cov-2","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/comments?post=237"}],"version-history":[{"count":1,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/237\/revisions"}],"predecessor-version":[{"id":239,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/237\/revisions\/239"}],"wp:attachment":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/media?parent=237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/categories?post=237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/tags?post=237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}